RxDoctor Payments Data

Philip Sullivan, MD

Cardiovascular Disease · Orchard Park, NYNPI 1538234661

Payments from drug & device makers

$3,723in general payments, 2019–2025

Across 236 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Boston Scientific$658
  • Novartis$503
  • Pfizer$356
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$235
  • E.r. Squibb & Sons, L.L.C.$207
  • plus $669 from 13 others
$19in research payments, 2019–2025

Across 1 payment — averaging $19.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$19

What the payments were for

  • Food & beverage$3,723100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,723 in reported general payments places this provider in the 65th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$45,226
Medicare patients
198
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$387,644
Repatha SureclickEvolocumab203$133,040
EntrestoSacubitril/Valsartan49$69,252
XareltoRivaroxaban41$49,873
JardianceEmpagliflozin17$24,606
Praluent PenAlirocumab18$11,645
Dabigatran EtexilateDabigatran Etexilate Mesylate15$7,357
Metoprolol Succinate283$5,735
Atorvastatin Calcium235$3,433
Rosuvastatin Calcium74$1,395
ClopidogrelClopidogrel Bisulfate124$1,336
Bumetanide33$1,004
Potassium Chloride48$944
Warfarin Sodium48$788
Furosemide103$760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$356$387,644268 claims
NovartisEntresto$503$69,25249 claims
Johnson & JohnsonXarelto$163$49,87341 claims
Boehringer IngelheimJardiance$36$24,60617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →